teaser
The UK’s first Academic Health Science Centre incorporating London’s St Mary’s and Hammersmith Hospitals, in partnership with Imperial College London, to test ValiMed™ in clinical pharmacy settings and engage in new product development.
The news following up on recent announcements regarding international expansion by announcing a partnership cooperation with the Imperial College Healthcare NHS Trust in London to test ValiMed in the Hammersmith and Charing Cross hospitals and to work together in developing new medication signatures including chemotherapy and cytostatic drugs.
The ValiMed Medication Validation System uses Enhanced Photoemission Spectroscopy to quickly validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety.
ValiMed compares a medication’s spectroscopic signature to the expected signature from the CDEX Medication Signature Library and returns an easy to understand “validated” or “not validated” result, requiring no user interpretation.
Earlier this month, CDEX announced publication of an 18 month independent study of the ValiMed™ Medication Validation System at the C.S. Mott Children’s Hospital in the University of Michigan Health System in the American Journal of Health-System Pharmacists. “During the 18 months since [ValiMed] was implemented, five potentially serious medication errors have been detected and avoided,” the report stated. “[ValiMed] consistently validated the correct solution, while dependably detecting as invalid the wrong drug or concentrations that departed substantially from the targeted standard.”
“We are delighted to have this opportunity to work in partnership with CDEX. By working in collaboration we will ensure product development is completely aligned with patient need to the mutual benefit of all,” said Professor Ann Jacklin, Chief Pharmacist at Hammersmith & Charing Cross hospitals, Imperial College Healthcare NHS Trust, and Visiting Professor at The School of Pharmacy University of London.
In 2000 Ms. Jacklin initiated the formation of the Centre for Medicines Safety and Service Quality, a joint research centre between Hammersmith Hospital and the School of Pharmacy, and has been joint Chair of the centre since this time.
“We are honored that Professor Jacklin and her staff have elected to partner with CDEX in testing the ValiMed technology and developing new applications and signatures that will dramatically increase patient medications safety where it is most needed” said Malcolm Philips, CDEX President and CEO. “This marks another step in developing a global coalition of world class hospitals working together to address major medication delivery issues.”
Read the full press release from University of Michigan
CDEX
Imperial College Healthcare Trust
